$98.2 Million is the total value of CAXTON CORP's 16 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 63.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $38,053,000 | -1.4% | 5,514,994 | +2.2% | 38.73% | -35.6% |
| SPY | Buy | SPDR S&P 500 ETF TRput | $19,358,000 | +26.7% | 77,052 | +22.0% | 19.70% | -17.3% |
| KALA | New | KALA PHARMACEUTICALS INC | $12,430,000 | – | 544,220 | +100.0% | 12.65% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $8,117,000 | +33.3% | 1,820,012 | +12.1% | 8.26% | -13.0% |
| Buy | GARRISON CAP INC | $7,166,000 | +1163.8% | 850,000 | +1137.2% | 7.29% | +724.2% | |
| MTEM | New | MOLECULAR TEMPLATES INC | $7,066,000 | – | 1,013,787 | +100.0% | 7.19% | – |
| BRKB | BERKSHIRE HATHAWAY INC DELcl b new | $1,640,000 | +8.3% | 8,945 | 0.0% | 1.67% | -29.4% | |
| JBGS | New | JBG SMITH PPTYS | $1,236,000 | – | 36,129 | +100.0% | 1.26% | – |
| New | INTEC PHARMA LTD JERUSALEM | $681,000 | – | 76,139 | +100.0% | 0.69% | – | |
| CMFN | Buy | CM FIN INC | $574,000 | +4.2% | 61,429 | +11.5% | 0.58% | -32.1% |
| GTXI | New | GTX INC DEL | $531,000 | – | 62,869 | +100.0% | 0.54% | – |
| ADNT | ADIENT PLC | $398,000 | +28.4% | 4,737 | 0.0% | 0.40% | -16.3% | |
| TMH | Sell | TEAM HEALTH HOLDINGS INC | $335,000 | -0.3% | 7,709 | -0.1% | 0.34% | -34.9% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $306,000 | -1.0% | 1,997 | +0.4% | 0.31% | -35.5% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $263,000 | -4.4% | 10,176 | +0.4% | 0.27% | -37.5% |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $95,000 | – | 16,198 | +100.0% | 0.10% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -12,456 | -100.0% | -0.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.